Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs

CONCLUSIONS: Overall, our study confirms the safety of TNFi and anti-IL in SpA patients, albeit with some caveats pertaining to solid cancers, OGID and fibromyalgia. Furthermore, taking into consideration causality with observational data may yield more reliable and relevant clinical information.PMID:37650298 | DOI:10.55563/clinexprheumatol/q38lu0

Source: Clinical and Experimental Rheumatology - August 31, 2023 Category: Rheumatology Authors: Laura Scagnellato Antonio Collesei Andrea Doria Giacomo Cozzi Mariagrazia Lorenzin Fabiola Atzeni Serena Bugatti Roberto Caporali Alberto Cauli Fabrizio Conti Addolorata Corrado Antonio Carletto Maria Sole Chimenti Rosario Foti Bruno Frediani Roberto Gerl Source Type: research